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Abst rac t
Introduction: Psoriasis is a chronic inflammatory skin disease with immunologic etiology.
Aim: To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 
(IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome.
Material and methods: This study included 60 patients with severe psoriasis.
Results: In patients with arterial hypertension concomitant with psoriasis, no statistically significant differences in 
cytokine levels were observed. On the other hand, in the group of patients diagnosed with diabetes, an increased 
level of IL-17 was observed. In patients with lipid disorders, the results were similar to the results of patients with 
diabetes.
Conclusions: It is very important to study immunologic mechanisms responsible for the presence and severity of 
psoriasis, in order to personalize the therapy in the future and optimize the effect of action on the basic disease 
and on concomitant disorders.
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Introduction
Psoriasis is a chronic inflammatory skin disease with 
immunologic etiology, depending on the activation of Th-1, 
Th-17 and Th-22 lymphocytes and dendritic cells [1]. In 
recent years, scientific research has been focusing on 
the identification of inflammatory pathways engaged 
in the pathogenesis of psoriasis. Several inflammatory 
cytokines are produced in skin lesions (TNF, IL-1, IL-6, 
IL-8, IL-17, IL-22, IL-23, VEGF, IFN-γ) [2]. It seems that these 
molecules are released into the circulatory system in 
a concentration depending on the severity and extent of 
the lesions [3, 4]. Furthermore, experimental and epide-
miologic studies indicate an association of increased lev-
els of interleukins, cytokines and hormones (adipokine) 
with cardiovascular diseases (CVD), metabolic syndrome 
(MetS), obesity and diabetes, defining psoriasis as a risk 
factor for the development of systemic diseases [2, 5, 
6]. Apart from chronic inflammation of skin, also other 
common risk factors should be considered (smoking, 
drinking alcohol), treatment used (immunosuppressive 
and changing the lipid profile), as well as common loci of 
predisposing genes [7].
Danielsen et al. proved that concomitant psoriasis 
is related to 3.8-fold higher risk of developing metabol-
ic syndrome in women aged 30 and 1.35-fold higher in 
men, independent of age [8]. Langan et al. [9] suggest 
performing screening tests for the features of metabolic 
syndrome in patients with severe psoriasis, as the risk of 
their occurrence significantly increases with the increase 
of the severity of skin lesions. Azfar et al. [10] report sig-
nificantly increased risk of occurrence of type 2 diabetes 
in patients with severe psoriasis (HR = 1.46). Ni et al. [5] 
found that the frequency of severe vascular episodes 
(infarction, stroke, cardiovascular death) in patients with 
psoriasis is significantly higher than in the group with-
out dermatosis (4.9% vs. 2.9%). These findings are also 
confirmed in the study by Armstrong et al. [11], giving an 
increase of the risk of infarction (RR = 1.29), stroke (RR = 
1.12) and death for cardiovascular reasons (RR = 1.39) in 
patients with psoriasis. 
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It is still an open question whether we can reduce the 
risk of the above incidents by appropriate treatment of 
skin lesions, in consequence reducing generalized inflam-
mation. Numerous studies [12–14] report that treatment 
with methotrexate (MTX) reduces the risk of developing 
CVD by 21–27% and the risk of myocardial infarction by 
18%. The mechanism of action remains unclear; MTX has 
been shown to downregulate foam cell production and in-
crease expression of anti-atherogenic reverse cholesterol-
transport protein [14]. To date, the positive influence of 
biopharmaceuticals has not been unambiguously con-
firmed. The National Psoriasis Foundation reports that 
anti-TNF drugs reduce the risk of cardiovascular episodes 
[15]. Most data concerning the use of ustekinumab are 
relatively short-term, but they suggest no influence of the 
drug on CVD. There are also single reports indicating re-
duced risk [11]. A meta-analysis of 34 studies concerning 
patients treated for psoriasis and psoriatic arthritis con-
firmed that methotrexate and anti-TNF reduce the risk of 
CVD in the absence of a protective effect of ciclosporin A, 
retinoids and anti-IL-12/23 [11, 16].
Aim 
The aim of the study was to investigate the levels 
of proinflammatory cytokines tumor necrosis factor α 
(TNF-α), interleukin 23 (IL-12), IL-23 and IL-17 in patients 
with psoriasis and psoriatic arthritis with concomitant 
metabolic syndrome in the context of individual compo-
nents of this syndrome (abdominal obesity, diabetes, ar-
terial hypertension, hyperlipidemia). Linking an elevated 
level of a specific interleukin with the presence of specific 
disorders in the course of psoriasis could influence thera-
peutic decisions and lead to personalization of therapy. 
Individual biopharmaceuticals against cytokines could 
additionally improve the parameters of metabolic dis-
eases and help to manage diabetes or hyperlipidemia. 
Material and methods
This study included 60 patients over 18 years of age 
(24 female and 36 male), diagnosed and treated for a se-
vere psoriasis (Psoriasis Area Severity Index (PASI), body 
surface area (BSA) > 10) in a dermatology clinic. Control 
groups were: 15 subjects diagnosed with metabolic syn-
drome and 15 healthy voluntary subjects. In both groups, 
the exclusion criteria were acute and chronic inflamma-
tory diseases with the exception of diabetes, hyperten-
sion and dyslipidemia.
For testing, venous blood (5 ml) was collected after the 
night rest. The concentrations of subunit p70 IL-12, IL-17 
and IL-23 and TNF-α in subjects’ sera were determined by 
the Quantikine test with enhanced sensitivity, with the 
ELISA method. The expected values were: IL-12 ND (be-
low) – 3.58 pg/ml; IL-17 below 31.2 pg/ml; IL-23 ND (below) 
– 40.5 pg/ml; TNF-α 0.550 – 2.816 pg/ml. The severity of 
psoriasis was evaluated with PASI and BSA scales. Psori-
atic arthritis was diagnosed based on the Caspar criteria. 
Metabolic syndrome was diagnosed based on the pres-
ence of revised National Cholesterol Education Program 
– Adult Treatment Panel III (NCEP-ATP III) criteria for meta-
bolic syndrome, according to American Heart Association/
The National Heart, Lung and Blood Institute (ANA/NHBLI). 
For conducting the above studies, the consent of the 
Bioethics Committee of Jagiellonian University was ob-
tained.
Statistical analysis
For the statistical assessment, the Statistica program 
was used (basic statistics, t-test, Mann-Whitney U-test, 
Spearman correlation). 
Results
In studied subjects, the average age was 49.4 ±16.4 
years; the youngest patient was 20, the oldest one was 82. 
The IL-12 level in all the subjects was indeterminable 
Figure 1. Serum concentrations of IL-17, IL-23 and TNF-α in the study and control group. Mann-Whitney U test was per-
formed to evaluate differences between the control and study group (mean ± SD, ± 1.96*SD)
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Figure 2. Levels of cytokines in patients with metabolic syndrome accompanying psoriasis in comparison to patients with 
a chronic dermatosis without the features of this syndrome (mean ± SD, ± 1.96*SD)
Figure 3. Levels of studied cytokines in patients with arterial hypertension concomitant with psoriasis (mean ± SD, 
± 1.96*SD)
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Figure 4. Levels of studied cytokines in patients with diabetes mellitus concomitant with psoriasis (mean ± SD, ± 1.96*SD)
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(< 0.78 pg/ml). The level of the studied cytokines IL-23 
and TNF-α was higher in patients diagnosed with psoria-
sis than in the control group: IL-23: 8.33 ±7.83 pg/ml vs. 
3.13 ±3.11 pg/ml; p < 0.05, 1 – β (false negative) = 0.998; 
TNF-α: 1.98 ±1.50 pg/ml vs. 1.13 ±0.42 pg/ml; p < 0.05, 
1 – β = 0.993 (Figure 1). Higher levels of IL-17 were ob-
served in patients with metabolic syndrome accompa-
nying psoriasis than in patients with a chronic derma-
tosis without the features of this syndrome: IL-17: 2.09 
±0.04 pg/ml vs. 4.06 ±3.00 pg/ml; p < 0.05, 1 – β = 0.973 
(Figure 2). Among the patients with psoriasis and psori-
atic arthritis, no correlation was observed between the 
level of cytokines and BMI. There were no correlations 
between the waist circumference and investigated cyto-
kines.
In patients with arterial hypertension concomitant 
with psoriasis, no statistically significant differences in 
interleukin levels were observed (IL-17: 2.15 vs. 3.19 pg/
ml, p = 0.22; IL-23: 8.25 vs. 8.37 pg/ml, p = 0.96; TNF-α: 
1.76 vs. 2.3 pg/ml, p = 0.17, 1 – β = 0.693 (Figure 3). On 
the other hand, in the group of patients diagnosed with 
diabetes, an increased level of IL-17 was observed (2.55 
vs. 5.4 pg/ml, p = 0.015) (Figure 4).
In patients with lipid disorders, the results were simi-
lar to the results of patients with diabetes. An increased 
level of IL-17 was observed (4.28 vs. 2.07 pg/ml, p = 0.02; 
1 – β = 0.776), while for the levels of other interleukins 
the obtained differences were statistically insignificant 
(IL-23: 10.58 vs. 7.65 pg/ml; p = 0.38 and TNF-α: 2.53 vs. 
1.82 pg/ml; p = 0.13) (Figure 5).
Discussion
The incidence of type 2 diabetes is significantly in-
creased in patients with psoriasis. Azfar et al. [10] claim 
that the presence of psoriasis is an independent risk fac-
tor for the development of type 2 diabetes. Importantly, 
Ucak et al. found that insulin resistance occurs with 
increased frequency in patients with psoriasis who are 
not obese [17]. Moreover, a positive correlation of insu-
lin resistance with PASI index was proven [18]. Previous 
studies state that the main mediators responsible for the 
development of insulin resistance are TNF-α, IL-6, leptin, 
adiponectin, or cytokines playing an important role in 
etiopathogenesis of psoriasis [19, 20]. Solomon et al. [21] 
found that the risk of diabetes development decreases 
in patients treated with TNF-α inhibitors compared to 
patients taking disease-modifying antirheumatic drugs 
(DMARD). Other studies also prove a decrease of insulin 
resistance with anti-TNF-α treatment [22]. Nevertheless, 
the results of studies on the influence of biopharmaceu-
ticals on diseases constituting components of metabolic 
syndrome – diabetes, hypertension and dyslipidemia – 
are different. 
Wu et al. [23] did not find significant changes as to 
the values of arterial pressure, blood glucose level and 
lipid profile in patients with psoriasis treated with TNF-α 
inhibitors compared to patients taking MTX. On the oth-
er hand, Famenini et al. [24] confirm a positive effect of 
anti-TNF-α therapy on reducing the risk of CVD develop-
ment; however, the influence of drugs on blood glucose 
profile is various (there are cases reporting hyper- as well 
as hypoglycemia after administration). There are no re-
ports concerning the influence of other biopharmaceuti-
cals used in psoriasis treatment (blocking IL-12/23, IL-17) 
on the development and course of metabolic diseases. 
Only Eiris et al. [25] found that in the Spanish population, 
genetic variability in IL-12B, IL-23R and IL-23A affects not 
only the risk of psoriasis development, but also occur-
rence and severity of type 2 diabetes. On the other hand, 
in recent years, the influence of Th17 lymphocytes and 
the IL-17/IFN-γ axis on the development of type 1 dia-
betes has been described [26, 27]. In the context of the 
above-mentioned reports, Roohi et al. [28] assessed the 
level of IL-17 and IL-23 in patients with type 1 and type 2 
diabetes. Our study showed a significantly increased level 
of IL-17 in patients with type 2 diabetes concomitant with 
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Figure 5. Levels of studied cytokines in patients with dyslipidemia concomitant with psoriasis (mean ± SD, ± 1.96*SD)
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psoriasis. No statistically significant differences in levels 
of IL-23 and TNF-α were found. Considering the described 
results, it is recommended to extend the study with the 
assessment of blood glucose levels and insulin resistance 
in patients treated with IL-17 inhibitors. A confirmation of 
the effect of the therapy on the course of diabetes and 
insulin resistance could indirectly significantly reduce the 
risk of CVD development and death [28].
The authors of a large systematic review covering 
2,400,000 patients reported that patients with psoriasis 
have a higher incidence of dyslipidemia than the general 
population [29]. Issues concerning the correlation of pso-
riasis, lipid metabolism and IL-17 were discussed in detail 
by Owczarczyk-Saczonek et al. [30] Varshney et al. [31] 
found that IL-17A leads to the accumulation of cholester-
ol in keratinocytes, which can play a crucial role in patho-
physiology of psoriasis. An increased level of IL-17 cor-
relates with a significant increase of intracellular level of 
cholesterol, which could explain frequent co-morbidity of 
psoriasis and dyslipidemia. According to our knowledge, 
no research has been performed directly concerning the 
level of IL-17 in patients with the described dermatoses 
and disorders of lipid profile. The results obtained in our 
study confirm the observations of Varshney et al., indi-
cating the level of IL-17 as important in the treatment of 
patients with dyslipidemia and psoriasis [31].
The correlation of arterial hypertension with cytokine 
profile is not so obvious, as the development of hyperten-
sion is also affected by the sympathetic system, renal 
disorders and vascular disorders [30]. The studies con-
ducted among patients with diabetes confirmed a signifi-
cantly elevated level of IL-17A in subjects with concomi-
tant hypertension compared to subjects with normal 
blood pressure [32]. It should also be noted that there 
are reports about the influence of briakinumab (inhibiting 
IL-12/23, and indirectly also IL-17) on the increase of risk 
of cardiovascular episodes, which affected the FDA deci-
sion about not approving the drug. No similar adverse 
reactions were observed after treatment with other 
anti-IL-12/23 and anti-IL-17 preparations [30]. The study 
conducted by us did not show a correlation of the levels 
of the analyzed cytokines with arterial hypertension in 
patients with psoriasis.
Conclusions
Biopharmaceuticals are the future for the treatment of 
many conditions with unconfirmed pathogenesis, includ-
ing psoriasis. Genome studies are being conducted with 
a view to evaluating the potential response and the time 
to develop resistance to biopharmaceuticals. It also seems 
very important to study immunologic mechanisms respon-
sible for the presence and severity of psoriasis, in order 
to personalize the therapy in the future and optimize the 
effect of action on the basic disease and on concomitant 
disorders, e.g. anti-IL-17 for patients with psoriasis with 
concomitant dyslipidemia and diabetes. Further detailed 
studies on the levels of cytokines in patients with psoriasis 
and metabolic syndrome are necessary.
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